On average, individuals may experience weight loss ranging from four to ten pounds per month
About 82% of people taking tirzepatide achieved at least 5% weight loss after one year, compared to 67% of those on semaglutide
Despite the rapid expansion of GLP-1RAs applications in fields such as endocrinology, cardiology, and neurology, their potential relevance in sepsis remains relatively underrepresented in the literature
By 2030, as many as one in four Americans may have tried them
recreational researchers are unaffected by either status
Clinical trials have demonstrated substantial weight reduction with tirzepatide, with participants losing an average of 1522% of their body weight over 72 weeks in the SURMOUNT-1 trial, depending on the dose administered